Dietary fat composition and cardiac events in patients with type 2 diabetes  by dos Santos, Ana Luiza Teixeira et al.
lable at ScienceDirect
Atherosclerosis 236 (2014) 31e38Contents lists avaiAtherosclerosis
journal homepage: www.elsevier .com/locate/atherosclerosisDietary fat composition and cardiac events in patients with type 2
diabetes
Ana Luiza Teixeira dos Santos 1, Tanara Weiss 1, Camila Kümmel Duarte 1,
Jorge Luiz Gross 1, Mirela Jobim de Azevedo 1, Themis Zelmanovitz*
Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2350/ Predio 12, 4 andar, CEP
90035-003 Porto Alegre, RS, Brazila r t i c l e i n f o
Article history:
Received 5 January 2013
Received in revised form
7 May 2014
Accepted 18 June 2014
Available online 25 June 2014
Keywords:
Dietary fatty acids
Type 2 diabetes
Cardiac events* Corresponding author. Serviço de Endocrinologia
Porto Alegre, Rua Ramiro Barcelos, 2350/Predio 12, 4
Alegre, RS, Brazil. Tel./fax: þ55 51 3359 8127, þ55 51
E-mail addresses: aninha.lu@terra.com.br (A.L.T. d
br (T. Weiss), camila.kummel@gmail.com (C.K. Duart
(J.L. Gross), mirelajobimazevedo@gmail.com (M.J. de
com.br (T. Zelmanovitz).
1 Tel./fax: þ55 51 3359 8127, þ55 51 3331 3312.
http://dx.doi.org/10.1016/j.atherosclerosis.2014.06.014
0021-9150/© 2014 Elsevier Ireland Ltd. All rights resea b s t r a c t
Objective: To evaluate associations of dietary fat composition with the development of cardiac events in
patients with type 2 diabetes, without ischemic heart disease who were followed for at least 12 months.
Methods: In this prospective cohort study the usual diet of patients was retrospectively assessed by a
3-day weighed diet record (WDR). Compliance with the WDR technique was assessed by comparing
protein intake estimated from 3-day WDR and 24-h urinary nitrogen output. The following were
considered cardiac events: myocardial infarction, myocardial revascularization procedures, congestive
heart failure, new-onset angina pectoris, and sudden death.
Results: A total of 227 patients with type 2 diabetes (aged 59 ± 10 years; 46.0% male), were followed
during 4.6 years. In a multivariate Cox regression analysis, the intake of polyunsaturated fatty acids had a
protective effect for cardiac events (HR ¼ 0.31, 95% CI: 0.11e0.89; P ¼ 0.03) adjusted for age, gender,
duration of diabetes, smoking, compliance with WDR, using hypolipidemic agents, and the presence of
hypertension and diabetic nephropathy. When the fat intake was divided into quartiles, the highest
intake of a-linolenic acid (>1.25% of energy) was negatively associated with cardiac events (HR ¼ 0.58,
95% CI: 0.39e0.85; P ¼ 0.006), adjusted for the same covariates..
Conclusion: In patients with type 2 diabetes without ischemic heart disease, a high intake of poly-
unsaturated fatty acids, especially alpha linolenic acid, was protective for the development of cardiac
events..
© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Cardiovascular disease (CVD) is the main cause of morbidity and
mortality in patients with diabetes mellitus. Coronary artery dis-
ease is more frequent and more severe in diabetic than non-
diabetic patients [1]. Diabetes itself, particularly due to sustained
hyperglycemia, greatly contributes to the severity of atherosclerotic
disease [2]. Additionally, the known high frequency of associated
cardiovascular risk factors in patients with diabetes, such as
obesity, dyslipidemia, and hypertension, can also explain the, do Hospital de Clínicas de
andar, CEP 90035-003 Porto
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rved.severity of CVD in diabetes. A cross-sectional, multicenter study
including 927 Brazilian outpatients with type 2 diabetes showed a
36% prevalence of coronary artery disease, a 33% of peripheral ar-
tery disease, and a 73% of hypertension in these patients [3].
Though hypolipidemic agents have shown the same effective-
ness for type 2 diabetic patients and nondiabetic patients, the
absolute rates of atherosclerotic cardiovascular disease events
remained elevated in patients with diabetes [4]. This reinforces the
importance of cardiovascular preventionmeasures based especially
on lifestyle interventions, such as dietary changes; these measures
should be implemented to mitigate cardiovascular risk factors.
Dietary intervention involves the management of the intake of
nutrients associated with cardiovascular protection and risk fac-
tors [5]. Current recommendations for the prevention and treat-
ment of CVD in diabetes suggest a diet rich in fruits, vegetables,
whole grains, walnuts, and low-fat dairy products, and salt re-
striction both for normotensive and hypertensive patients [6,7].
The speciﬁc recommendations are: reduction in saturated fatty
A.L.T. dos Santos et al. / Atherosclerosis 236 (2014) 31e3832acids (SFAs) and cholesterol intake; restriction of trans fatty acids
(FA) intake; increase in total ﬁber intake and increase in con-
sumption of ﬁsh (as a source of polyunsaturated FA (PUFA) [6,7].
However, the scientiﬁc evidence for these recommendations is
generally based on studies conducted with non-diabetic subjects.
Furthermore, the effects of dietary fat intake on CVD prevention
could be different in patients with and without diabetes, since
diabetes has been associated with lipid abnormalities and a pro-
thrombotic proﬁle [8].
The aim of the present study was to evaluate the association
between dietary fat composition and the development of cardiac
events in patients with type 2 diabetes and without ischemic heart
disease. In addition, the role of adherence to current cardiovascular
dietary recommendations in the prevention of cardiac events was
evaluated.
2. Patients and methods
2.1. Patients
We carried out a retrospective data analysis of patients with
type 2 diabetes belonging to a prospective cohort study. The pa-
tients included in the study were from the Diabetes research
outpatient clinic at Hospital de Clínicas de Porto Alegre (Rio Grande
do Sul, Brazil) andwere followed for at least 12months. At baseline,
the patient exclusion criteria were: presence of ischemic heart
disease, body mass index (BMI) > 40 kg/m2, serum creatinine
>1.5 mg/dl, heart failure, symptomatic autonomic neuropathy
(gastroparesis or diabetic diarrhea), dietary counseling by a regis-
tered dietitian during the previous 12 months, and inability to
perform the weighed diet records (WDR). The study was approved
by the Hospital Ethics Committee; all patients signed a written
informed consent form.
All patients underwent a standardized clinical, nutritional and
laboratory examination at baseline. A three-day WDR was carried
out, 24-h urine was collected, and on the 3rd day (after patients
fasted overnight), blood samples were also collected. During the re-
evaluation period, patients were submitted to the same clinical and
laboratory examinations.
The follow-up was determined as the period between the ﬁrst
assessment and the date of a ﬁrst cardiac outcome, death, or the last
medical evaluation. Patients were divided into two groups ac-
cording to the presence of cardiac outcomes at the end of the study.
2.2. Methods
2.2.1. Dietary assessment
Diet was assessed using a 3-day WDR technique (two noncon-
secutive weekdays and one day of the weekend). Patients were
issued commercial scales (1e125 g) and measuring cups
(25e250 mL; Pirex) and given a detailed explanation and demon-
stration of the procedures by a trained, registered dietitian. Next,
patients performed a training session for a one-day WDR. The
3-day WDR was performed over two to three weeks and before
nutritional recommendations for all patients (Fig. 1).
Compliance with the WDR technique was assessed by compar-
ison of protein intake estimated from the 3-dayWDR (PI-WDR) and
from the 24-h urinary nitrogen output (PI-N) performed on the
third day of the WDR period [9]. According to Vaz et al. [9], patient
compliance with the WDR protocol is established if the PI-WDR/PI-
N ratio remain between 0.79 and 1.26.
The analysis of dietary nutrients from the 3-day WDRs was
performed using the Nutribase Clinical Nutritional Manager soft-
ware (version 7.14, 2007). The mean values of each nutrient
consumed during the 3-day WDR were calculated. Nutritional datafor frequently consumed foods were updated if necessary, and/or
complemented with data obtained from local manufacturers of
industrialized foods.
Patients were classiﬁed as adherent or non-adherent according
to reaching or not each dietary fat goal based on American Diabetes
Association (ADA) recommendations [6]. The items of ADA fat
intake recommendations are: SFA below 7% of energy/day;
cholesterol below 200 mg/day; increasing the intake PUFA, and
reducing the intake of trans FAs. Besides using established cutoff
points values of ADA dietary recommendations, we also catego-
rized patients as adherent or non-adherent according to the fat
intake of all studied sample: above or below themean (for PUFA) or
median (for trans FAs), and according to the quartiles of nutrient
intake (for PUFA).
2.2.2. Anthropometric measurements
The body weight and height of patients (without shoes or coats)
were collected with an anthropometric scale; measurements were
recorded to the nearest 100 g for weight, and to the nearest 0.1 cm
for height. Waist circumference was measured midway between
the lowest rib and the iliac crest, near the umbilicus.
2.2.3. Clinical evaluation at baseline and end-of-study
The clinical assessment emphasized cardiovascular evaluation
(blood pressure, WHO cardiovascular questionnaire, resting elec-
trocardiogram, and evaluation of peripheral arterial pulses) and
renal function.
Patients were classiﬁed as “nonsmoker” or “smoker” (smoker in
the past or currently a smoker). Physical activity was classiﬁed into
four levels based on a standardized questionnaire, which was
adapted to local habits [10].
Mean blood pressure was calculated based on two separate
measures using a digital sphygmomanometer (OMRON® Automatic
Blood Pressure Monitor, Model HEM-705CP, Vernon Hills, Illinois
60061). Hypertension was deﬁned as blood pressure 140/
90 mmHg or use of antihypertensive drugs on at least two separate
occasions.
Presence of baseline ischemic heart disease, an exclusion
criterion, was deﬁned as: presence of angina and/or possible
infarction, using a World Health Organization (WHO) cardio-
vascular questionnaire as previously standardized in patients
with type 2 diabetes by our group [11], or abnormalities on
resting electrocardiogram (Minnesota Codes: Q and QS patterns
[1-1 to 1-3]; S-T junction and segment depression [4-1 to 4-4];
T-wave items [5-1 to 5-3], or complete left bundle branch block
[7-1]). In those cases, the ischemic heart disease was always
conﬁrmed by exercise electrocardiogram or radionuclide
myocardial perfusion imaging with stress (exercise or pharma-
cological) compatible with the presence of myocardial ischemia
[12].
Peripheral vascular disease was determined based on the
presence of intermittent claudication and/or absence of posterior
tibial pulse at clinical examination. The presence of cerebrovas-
cular disease was established if there was a history of cerebro-
vascular accident (ischemic stroke) and/or compatible ﬁndings
(sequelae).
Renal function was evaluated by serum creatinine and urinary
albumin excretion [12]. The diagnosis of increased urinary albumin,
microalbuminuria (24-h urinary albumin excretion between 30 and
300 mg) or macroalbuminuria (24-h urinary albumin excretion
300 mg), was conﬁrmed by a second measurement [12,13].
2.2.4. Cardiac outcomes
Cardiac endpoints were deﬁned when a new cardiac event
occurred (myocardial infarction [Minnesota codes 1-1 to 1-3 or 7-1
Fig. 1. Diagram of the study design.
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scintigraphy (necrosis), or an episode of chest pain with a
compatible ECG], congestive heart failure [class III and IV of the
New York Heart Association classiﬁcation], sudden death [death
within 24 h after the last time the patient was seen alive in his/her
usual state [14]] or death of cardiac origin), myocardial revascu-
larization procedures, and new onset of angina pectoris (WHO
cardiovascular questionnaire). Abnormal resting ECG and new
onset of angina pectoris were considered as cardiac outcomes only
after stress myocardial scintigraphy (exercise or dipyridamole)
conﬁrmation.
2.2.5. Laboratory analyses
Glycemic control was evaluated by serum glucose (glucose-
peroxidase colorimetric enzymatic method) and glycated hemo-
globin (high precision chromatography, Merck-Hitachi 9100
apparatus). The lipid proﬁle consisted of the measurement of total
cholesterol and triglycerides using colorimetric assay. HDL
cholesterol was measured using the direct enzymatic method. LDL
cholesterol was calculated using the Friedewald formula. Serumcreatinine was measured by the Jaffe method and urea by kinetic
UV assay. Urinary albumin excretion was evaluated by the immu-
noturbidimetry technique (Kit MICROALB, AMES) [15].
3. Statistical analyses
Student t test, ManneWhitney U test, and the Exact Fisher or
ChieSquare tests were applied. Multivariate Cox's proportional
hazard model was used to estimate the risk factors for the presence
of cardiac outcomes (dependent variables). Different models were
generated to evaluate the association of each nutrient (indepen-
dent variables) with cardiac events. Independent variables were
selected based on their signiﬁcance (P < 0.10) at univariate analysis
or according to their biological relevance. The independent vari-
ables were selected based on at least ten cardiac outcomes for each
putative predictor.
Data were expressed as mean ± standard deviation, or as me-
dian (P25 e P75) unless otherwise stated. The level of signiﬁcance
adopted was 5%. The software SPSS 18.0 (SPSS®, Chicago, IL) was
used for the analysis.
Table 2
Daily dietary intake of patients with type 2 diabetes categorized according to the
development of cardiac events.
Without cardiac
events (n ¼ 191)
With cardiac
events (n ¼ 36)
P
Energy (Kcal) 1794 ± 469 1656 ± 522 0.11
Carbohydrates (% of energy) 47 ± 7 46 ± 10 0.79
Proteins (% of energy) 19 ± 3 19 ± 3 0.75
Lipids (% of energy) 34 ± 7 32 ± 7 0.31
Saturated FA (% of energy) 9 ± 3 10 ± 2 0.73
Monounsaturated FA (% of energy) 10 ± 3 10 ± 2 0.81
Polyunsaturated FA (% of energy) 10 ± 3 9 ± 3 0.10
ALA (% of energy) 0.97 ± 0.49 0.81 ± 0.43 0.07
Linoleic FA (% of energy) 8.51 ± 3.23 7.70 ± 2.90 0.16
EPA (% of energy) 0.00 (0.00e0.01) 0.01 (0.00e0.03) 0.69
DHA (% of energy) 0.01 (0.00e0.02) 0.01 (0.00e0.04) 0.79
Arachidonic FA (% of energy) 0.05 (0.03e0.08) 0.05 (0.04e0.08) 0.95
Trans FA (% of energy) 1.2 ± 0.7 1.3 ± 0.8 0.53
P/S Ratio 1.1 ± 0.4 0.9 ± 0.4 0.08
Cholesterol (mg) 210 ± 99 193 ± 94 0.36
Total ﬁber (g/1000 Kcal) 11 ± 4 11 ± 3 0.65
Data are expressed as mean ± SD or median (p25-p75). FA: fatty acid; ALA:
a-linolenic acid; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; P/S ratio:
polyunsaturated/saturated fat ratio.
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4.1. Characteristics of patients according to cardiac events
A total of 236 patients underwent clinical, laboratory, and
nutritional evaluation at baseline. Nine patients were unable to
attend the medical visits or declined participation in the study and
thus did not perform the re-evaluation. Therefore, the study
included 227 patients (96.2% of the initial population; 106 male)
who were followed for 4.6 years (from one to 8.6 years). The mean
age of patients was 59 ± 10 years, duration of diabetes 12 ± 8 years,
and BMI 28.6 ± 4.0 kg/m2. Thirteen deaths occurred during follow
up: one patient died due to cardiac reasons and 12 patients from
other causes (complications due to systemic lupus erythematosus,
sepsis, postoperative complications, neoplasms, and respiratory
insufﬁciency).
During the follow-up, the following cardiac events were iden-
tiﬁed in 36 patients: myocardial infarction (n ¼ 3), myocardial
revascularization procedures (n ¼ 4), congestive heart failure
(n ¼ 2), and new-onset angina pectoris (n ¼ 27). Clinical and lab-
oratory characteristics of patients at baseline according to cardiac
outcome are shown in Table 1. The patients who presented cardiac
events had diabetes for a longer period of time. The other charac-
teristics were not different between the two groups. It should be
noted that the low percentages of hypolipidemic agents occurred
because this information was recorded at baseline when patients
did not have a diagnosis of ischemic heart disease. At the end-of-
study, the proportion of patients using hypolipidemic drugs was
90% and 57% in the group with and without cardiac events,
respectively (p ¼ 0.01).
4.2. Diet characteristics and cardiac events
Compliancewith theWDR techniquewas observed in 88% in the
group with cardiac events and 83% in the group with no cardiac
event (P ¼ 0.41). WDR were obtained in all seasons (27.9% in the
winter, 18.6% in the summer, 26.1% in the fall and 27.4% in the
spring; P ¼ 0.79).Table 1
Baseline clinical and laboratory characteristics of patients with type 2 diabetes
categorized according to the development of cardiac events.
Without cardiac
events (n ¼ 191)
With cardiac
events (n ¼ 36)
P
Age (years) 59 ± 10 62 ± 9 0.09
Male 44% 58% 0.15
Ethnicity: White 88% 87% 1.0
Duration of diabetes (years) 12 ± 7 14 ± 9 0.04
BMI (kg/m2) 28.6 ± 4.1 28.9 ± 4.6 0.72
Hypertension 74% 85% 0.27
Diabetic nephropathy 32% 50% 0.06
Smoking (self-reported) 49% 58% 0.36
Alcohol (self-reported) 44% 42% 1.0
Sedentary lifestyle 51% 66% 0.14
Diabetes treatment
(D/OA/I or I þ OA)
3%/61%/36% 3%/65%/32% 1.0
ACE inhibitors 55% 54% 1.0
Beta-blockers 31% 25% 0.68
Hypolipidemic agents 22% 9% 0.15
Fasting plasma glucose (mg/dL) 151 ± 56 150 ± 53 0.90
Glycated hemoglobin (%) 7.5 ± 1.5 7.2 ± 1.4 0.32
Total cholesterol (mg/dL) 204 ± 43 198 ± 56 0.42
HDL cholesterol (mg/dL) 53 ± 30 51 ± 13 0.79
LDL cholesterol (mg/dL) 125 ± 38 132 ± 37 0.33
Triglycerides (mg/dL) 133 (95e201) 136 (121e166) 0.57
Data are expressed as mean ± SD, patients with the characteristic (%), or median
(P25eP75). BMI: body mass index; Diabetes treatment: D: diet; OA: oral agents; I:
insulins. ACE: angiotensin converting enzyme.The daily dietary intake evaluated by 3-day WDR of patients
with type 2 diabetes, categorized according to the development of
cardiac events, is shown in Table 2. There were no differences be-
tween energy and macronutrient intakes of patients with and
without cardiac events.
The fractions of daily dietary PUFA were also evaluated. In
relation to n-3 PUFA intake, a-linolenic acid (ALA) was the most
frequently consumed, with a trend to a lower intake in patients
with cardiac events than in patients without cardiac events
(0.81 ± 0.43% vs. 0.97 ± 0.49%, respectively; P ¼ 0.07). Multivariate
analysis showed that the intake of ALA was negatively associated
with the development of cardiac events (HR 0.28, 95% CI 0.09e0.81;
P ¼ 0.019), adjusted for age, gender, duration of diabetes, smoking,
compliance with WDR, using hypolipidemic agents, and presence
of hypertension and diabetic nephropathy. When we repeated
multivariate analysis including the current use of hypolipidemic
agents in the model, the inverse association of ALA intake with
cardiac events remained signiﬁcant. Regarding n-6 PUFA intake,
linoleic acid, the principal component, did not differ between the
two groups (7.69 ± 2.81 vs. 8.50 ± 3.23%, respectively; P ¼ 0.16).
Moreover, no statistical differencewas observed for other evaluated
PUFA: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA),
and arachidonic acid.
Soybean oil was the most widely consumed vegetable oil (70%);
other oils consumed included corn, rice or the combination of more
than one type of oil. The proportion of soybean oil intake of patients
with cardiac events was signiﬁcantly lower (55%) than the pro-
portion for patients without end-of-study cardiac events (73%;
P ¼ 0.042). In relation to other foods sources of n-3 PUFA, only 14%
of patients consumed marine foods, with no difference between
patients with (24%) and without (13%) cardiac events. The negative
association between the intake of ALA and the development of
cardiac events remained signiﬁcant in multivariate analysis,
adjusted for age, gender, duration of diabetes, smoking, compliance
with WDR, using hypolipidemic agents, presence of hypertension
and diabetic nephropathy, and also soybean oil intake.
4.3. Dietary adherence according to fat diet recommendations and
cutoff points of fat intake and cardiac events
Adherence to current cardiovascular dietary recommendations
was compared in patients with and without cardiac outcomes at
Fig. 2. Multivariate Cox regression analysis to evaluate the association between the incidence of cardiac events (dependent variable) and alpha linolenic acid intake of type 2
diabetes patients; patients were divided according to the quartiles of intake of this nutrient: 0.6% of energy ¼ blue line; 0.61e0.86% of energy ¼ green line; 0.87e1.24% of
energy ¼ yellow line; and >1.25% of energy ¼ purple line. The analysis was adjusted for age, gender, duration of diabetes, smoking, compliance with WDR, using hypolipidemic
agents, and presence of hypertension and diabetic nephropathy. P ¼ 0.006.
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point >9.5% of energy was deﬁned (based on themean intake of the
227 patients studied). The proportion of patients with cardiac
events and who adhered to PUFA recommendations was signiﬁ-
cantly lower than that of the patients without cardiac events (28 vs.
48%; P ¼ 0.03). The multivariate analysis showed that the intake of
PUFA >9.5% of energy was negatively associated with the devel-
opment of cardiac events (HR 0.31 95% CI 0.11e0.89; P ¼ 0.03),
adjusted for age, gender, duration of diabetes, smoking, compliance
with WDR, using hypolipidemic agents, and presence of hyper-
tension and diabetic nephropathy. There were no signiﬁcant dif-
ferences in the proportion of patients with and without cardiac
outcomes that adhered to SFA (14 vs. 17%, respectively; P ¼ 0.81)
and cholesterol intake recommendations (61 vs. 50%, respectively;
P ¼ 0.28). Similarly, the proportion of patients with cardiac events
who consumed 1.05% of energy of trans FA (adherents) was not
different from the patients without cardiac events (52 vs. 50%;
P ¼ 1.00).
4.4. Analyses according to quartiles of PUFA intake and cardiac
events
Fractions of PUFA were analyzed according to the quartiles of
intake. The quartiles of ALA intake were linearly associated with a
decrease in cardiac events, as follows: 1st quartile (0.60% of en-
ergy): 38.9% of cardiac events; 2nd quartile (0.61e0.86% of energy):
27.8% of cardiac events; 3rd quartile (0.87e1.24% of energy): 19.4%
of cardiac events; and 4th quartile (>1.25% of energy): 13.9% ofcardiac events (P for trend ¼ 0.01). This inverse association was
conﬁrmed by a multivariate analysis using the 1st quartile of ALA
intake as the reference: HR 0.58, 95% CI 0.39e0.85; P ¼ 0.006
(Fig. 2). This analysis was adjusted for age, gender, duration of
diabetes, smoking, compliance with WDR, using hypolipidemic
agents, and presence of hypertension and diabetic nephropathy.
5. Discussion
The current study demonstrated a negative association of PUFA
intake with the incidence of cardiac events in a cohort of patients
with type 2 diabetes. The association was also shownwhen the use
of hypolipidemic agents and cardiovascular risk factors were taken
into consideration. The protective role of PUFA intake was espe-
cially signiﬁcant for ALA consumption. PUFA intake equal to or
higher than 9.5% of total energy was associated with up to 70.0%
risk reduction for cardiac events. The highest intake of ALA (largest
quartile: >1.25% of energy) was associated with a 42% reduction in
risk.
The beneﬁt of the intake of n-3 PUFA on primary and secondary
prevention of CVD in individuals without diabetes has been
demonstrated in observational and clinical trials [16], both as a
result of dietary supplementation [17] and increased ﬁsh con-
sumption [18]. Furthermore, a cardioprotective effect of ALA has
also been suggested by a number of observational studies; most
studies [19,20], but not all [21], have shown an inverse association
between ALA intake and ischemic heart disease. Recently, a meta-
analysis of prospective and retrospective studies reinforced the
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observational studies, higher ALA exposure was associated with a
moderately lower risk of CVD. In the pooled dietary analyses, each
1-g/day increment of ALA intake was associated with a 10% lower
risk of coronary heart disease death. However, the beneﬁcial effect
of ALA intake probably did not occur for others cardiac outcomes
such as the incidence of congestive heart failure [23].
The beneﬁcial effects of ALA intake for CVD may be associated
with slowing down the formation and calciﬁcation of atheroscle-
rotic plaque [24]. Other related mechanisms are plaque stabiliza-
tion [25] and antiarrhythmic effects [26], either directly or through
desaturation and elongation of ALA into EPA.
The varied beneﬁcial effects of ALA intake on cardiovascular
outcomes in different populations might be inﬂuenced by the di-
etary consumption of EPA and DHA [27]. It is possible that ALA may
reduce the risk of ischemic heart disease among subjects with low
consumption of these long-chain n-3 PUFA. Among American men
with little (<100 mg/day) or no n-3 long-chain PUFA intake, each
1 g of daily ALA intake was associated with a 47% reduction in the
ischemic heart disease risk [28]. In the present study, the mean EPA
and DHA intake was ~70 mg/day; this level of intake is considered
low. However, other authors considered that the association be-
tween ALA intake and CVD risk is independent of EPA/DHA intake
[29,30]. In a Chinese population-based cohort, individuals in the
highest quartile of EPA/DHA (0.46 ± 0.18 g/day) and ALA
(0.80 ± 0.36 g/day) intake, had a 33% lower risk of cardiovascular
mortality (HR 0.67, 95% CI 0.57e0.78) as compared with subjects in
the lowest quartiles of both types (EPA/DHA ¼ 0.19 ± 0.10 g/day;
ALA ¼ 0.40 ± 0.11 g/day) [29]. The inverse association between ALA
intake and cardiovascular mortality persisted along the quartiles of
EPA/DHA intake and even decreased in the lowest one. Reinforcing
the possible independent cardiovascular effect of ALA consumption
from the amount of EPA and DHA intake, the Nurses' Health Study
cohort also demonstrated an inverse association between the
highest intake of ALA and sudden cardiac death [30]. Further
studies are needed to determine whether the protection for car-
diovascular events of dietary ALA intake is inﬂuenced or not by EPA/
DHA consumption.
The ALA intake, instead of soybean oil itself, is probably
responsible for the beneﬁcial effects demonstrated in the heart.
Firstly, as we demonstrated, the negative association between ALA
intake and cardiac events remained signiﬁcant even after being
adjusted for soybean oil intake. Second, ALA represents a lower
proportion of FA (~7%) in the composition of soybean oil as
compared with linoleic acid (51%), oleic acid (22.8%), and palmitic
acid (10.3%). Furthermore, we did not ﬁnd an association of these FA
with the development of cardiac events.
In patients with diabetes, the beneﬁcial effects of PUFA in the
progression of CVD [31], as well as in relation to the cardiovascular
risk proﬁle [32,33] was demonstrated in cross-sectional [32] and
observational [34] studies, and in clinical trials [35,36]. A large fe-
male cohort study of type 2 diabetic patients without coronary
heart disease showed an inverse association of n-3 PUFA intake
(from ﬁsh consumption) with the incidence of coronary heart dis-
ease and total mortality [34]. In that study, diet was evaluated by
food frequency questionnaires answered bymail; the questionnaire
is not a comparable tool in relation to the WDR technique used in
the present study [37]. Additionally, few randomized controlled
trials evaluated the effects of the intake of n-3 PUFA on diabetic
CVD and only patients with previous macrovascular disease
[35,36,38] or with high cardiovascular risk [39] were included.
Moreover, these studies evaluated n-3 effects from supplements
and not from dietary sources and a beneﬁcial effect on the pro-
gression of the CVD was demonstrated in some of them [35,36]. On
the other hand, in the ORIGIN trial, a recent trial conducted in pre-diabetes and diabetic patients, the n-3 supplementation did not
reduce the incidence of cardiovascular events in the presence of
CVD [38].
One possible concern associated with n-3 PUFA intake is the
deterioration of glycemic control associated with high supplement
doses in diabetic subjects [40]. Since hyperglycemia has been
associated with an increase in the incidence of CVD [2], this un-
desirable effect could attenuate the protective cardiovascular ef-
fects of n-3 PUFA. However, this deleterious impact on glycemic
homeostasis was not conﬁrmed [41,42] andwas observed only with
high consumption of ﬁsh oil and not with moderate intake of n-3
PUFA frommarine or plants sources. Regarding the lipid proﬁle, n-3
PUFA intake in diabetic patients seems to have a similar effect as in
non-diabetic patients. n-3 PUFA intake decreases serum tri-
glycerides, a dose dependent effect that is inﬂuenced by baseline
plasma triglyceride levels [42]. Moreover, n-3 consumption might
cause a small and controversial increase in HDL and LDL cholesterol
levels [41,42].
In the current study, although we demonstrated that ALA intake
was a protective factor against the development of cardiac events,
we could not demonstrate the expected favorable effect from other
n-3 FAs such as EPA and DHA [36]. The absence of this protective
effect may have occurred due to the main intake of n-3 PUFA being
fromvegetable oils, especially soybean oil; this oil is rich in ALA and
represented 70% of the total oil consumed by our patients. More-
over, only 14% of patients consumed marine foods, such as ﬁsh,
which are known to be rich sources of EPA and DHA. The availability
of ﬁsh and other marine products is limited in many countries [43]
and ALA from plant oils and nuts is the predominant source of n-3
PUFA in the typical Western diet. Perhaps, ALA may be a car-
dioprotective alternative and could be of great importance for
public health.
Regarding to the absence of association between EPA and DHA
intake and incidence of cardiac events in our study, it is important
to emphasize that this subject remains inconclusive. Previous
randomized, double-blind, placebo-controlled trials reported the
efﬁcacy of n-3 fatty acid supplements in the secondary prevention
of CVD [44]. However, a recently published meta-analysis showed
that there is insufﬁcient evidence for a secondary preventive effect
of EPA and DHA supplements against overall cardiovascular events
among patients with a history of CVD [45].
In the present study, we did not ﬁnd an association between
SFA intake and the incidence of cardiac events. Although the
recommendation is to reduce the intake of SFA to <7% of energy,
which is considered level A of evidence according to the current
guidelines [6], the recommendation is based on studies that
analyzed the effect of changes in the SFA content performed only
in individuals without diabetes [46,47]. Our ﬁndings are consis-
tent with results from the meta-analysis of prospective cohort
studies that evaluated the association of saturated fat with CVD;
the study showed no signiﬁcant evidence for an increased risk of
ischemic heart disease or CVD [48]. On the other hand, a recent
meta-analysis of randomized controlled trials that evaluated the
effect of dietary fat manipulation on cardiovascular mortality and
morbidity, suggested that dietary saturated fat reduction (through
reduction and/or modiﬁcation of dietary fat) may be protective of
cardiovascular events, reducing them by 14% [49]. However, it is
important to emphasize that this cardioprotective effect was seen
in studies of men (not of women) and of individuals with mod-
erate or high cardiovascular risk at baseline. Moreover, this pro-
tective effect was more clearly observed when saturated fat was
replaced with unsaturated fats and not with carbohydrates. So,
the relationship between SFA and ischemic heart disease remains
controversial and further studies are needed to clarify this
question.
A.L.T. dos Santos et al. / Atherosclerosis 236 (2014) 31e38 37One major limitation of our study was that the dietary assess-
ment was performed at baseline only and modiﬁcations of dietary
habits during the follow up could have been missed. However, our
dietary data were accurate. We used a standardized 3-day
weighed-diet record technique, which includes a 24-h urinary
urea measurement to conﬁrm dietary intake estimated from re-
cords [50]. In fact, this dietary tool has been largely used to conﬁrm
dietary compliance in studies with diabetic patients [32,51,52].
Also linked to dietary data limitation, the measurement of a
biological marker of fat intake would have reinforced our results. In
fact, serum fatty acids have been used to evaluate fat intake in
patients with type 2 diabetes [53]. Another limitation is that the
relatively small sample size of our cohort could have accounted for
the small proportion of traditional hard cardiac outcomes. In our
sample new onset of angina represented almost 65% of the
observed cardiac endpoints, and it can be considered a soft cardiac
endpoint. However, the identiﬁcation of new onset angina
(myocardial ischemia) was always conﬁrmed by stress myocardial
scintigraphy (exercise or dipyridamole). Finally, the retrospective
data analyses of patients who belong to a prospective cohort study
might be considered as a study weakness. However, all patients
were treated in the same outpatient division by the same experi-
enced team using a standardized clinical and laboratory protocol.
This cohort has been prospectively followed by our research group
since 2000 [9,32,51e53]. Exposure precedes the disease with
acceptable conﬁdence in this scenario.
6. Conclusion
The present study suggests an association between PUFA intake,
especially ALA, with the prevention of cardiac events in patients
with type 2 diabetes. Additional studies, especially randomized
controlled clinical trials, are needed to conﬁrm these ﬁndings in
diabetic patients both with and without ischemic heart disease.
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